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Caffeine Ingestion Does Not Alter Performance
During a 100-km Cycling Time-Trial Performance
Angus M. Hunter, Allan St. Clair Gibson, Malcolm Collins,
Mike Lambert, and Timothy D. Noakes
This study analyzed the effect of caffeine ingestion on performance during a
repeated-measures, 100-km, laboratory cycling time trial that included bouts of
1- and 4-km high intensity epochs (HIE). Eight highly trained cyclists partici-
pated in 3 separate trials—placebo ingestion before exercise with a placebo
carbohydrate solution and placebo tablets during exercise (Pl), or placebo in-
gestion before exercise with a 7% carbohydrate drink and placebo tablets dur-
ing exercise (Cho), or caffeine tablet ingestion before and during exercise with
7% carbohydrate (Caf). Placebo (twice) or 6 mg · kg–1 caffeine was ingested 60
min prior to starting 1 of the 3 cycling trials, during which subjects ingested
either additional placebos or a caffeine maintenance dose of 0.33 mg · kg–1
every 15 min to trial completion. The 100-km time trial consisted of five 1-km
HIE after 10, 32, 52, 72, and 99 km, as well as four 4-km HIE after 20, 40, 60,
and 80 km. Subjects were instructed to complete the time trial and all HIE as fast
as possible. Plasma (caffeine) was significantly higher during Caf (0.43 ± 0.56
and 1.11 ± 1.78 mM pre vs. post Pl; and 47.32 ± 12.01 and 72.43 ± 29.08 mM pre
vs. post Caf). Average power, HIE time to completion, and 100-km time to
completion were not different between trials. Mean heart rates during both the
1-km HIE (184.0 ± 9.8 Caf; 177.0 ± 5.8 Pl; 177.4 ± 8.9 Cho) and 4-km HIE
(181.7 ± 5.7 Caf; 174.3 ± 7.2 Pl; 175.6 ± 7.6 Cho; p < .05) was higher in Caf than
in the other groups. No significant differences were found between groups for
either EMG amplitude (IEMG) or mean power frequency spectrum (MPFS).
IEMG activity and performance were not different between groups but were
both higher in the 1-km HIE, indicating the absence of peripheral fatigue and
the presence of a centrally-regulated pacing strategy that is not altered by
caffeine ingestion. Caffeine may be without ergogenic benefit during endur-
ance exercise in which the athlete begins exercise with a defined, predeter-
mined goal measured as speed or distance.
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Introduction
The modern interest in the possible performance-enhancing effects of caffeine were
initially raised by the finding of Costill and co-workers (8, 12, 21) that caffeine
ingestion prior to exercise increased time to exhaustion or the amount of work that
could be performed in a known time.
An early theory was that caffeine effects substrate metabolism during exer-
cise. The glucose–fatty acid cycle theory (35) postulated that caffeine would en-
hance performance by increasing fat oxidation during exercise, thereby reducing
the rate of muscle glycogen use. Since muscle glycogen depletion is believed to be
the principal determinant of exhaustion during prolonged exercise, this effect of
caffeine would delay the onset of terminal glycogen depletion, thereby enhancing
performance (12).
More recently, there has been a considerable increase in evidence (48) sup-
porting a substantial ergogenic effect of caffeine on endurance but not sprint activi-
ties (10, 15, 18, 34). The vast majority of those studies showing an ergogenic effect
of caffeine on endurance exercise have evaluated performance during open-ended
cycling (1, 2, 17, 22, 33) or running (10, 14) trials in which subjects maintain the
same exercise intensity for as long as possible.
It is difficult to extrapolate findings from time-to-exhaustion trials to human
sporting performance, since most human competitive sport requires either that a
specified distance must be completed as rapidly as possible or, much less com-
monly, as much distance as possible must be covered in a given time, also fixed and
known before the exercise begins.
To our knowledge, very few studies have evaluated the effects of caffeine
ingestion on performance during a prolonged laboratory trial in which the endpoint
is predetermined, not open-ended as in the majority of the reported studies. It is
known that inter-test variability is substantially reduced in this form of closed trials
compared to open-ended trials (37). However the very marked ergogenic effect of
caffeine in the open-ended trials that have been reported (2, 10, 14, 17, 22, 33),
precluded the possibility that a false positive finding might have resulted from the
relative insensitivity of that experimental method.
Although an ergogenic effect of caffeine has been reported in runners (46),
cyclists (25), and rowers (5) who completed closed performance time trials in which
a specified distance was completed in a faster time after caffeine ingestion, the
duration of these trials were relatively brief, lasting from 4 min (46) to 60 min (25).
There are good reasons why the effects of caffeine-ingestion should also be
investigated during exercise in which the endpoint is predetermined and the dura-
tion of exercise is more prolonged—for example, hours rather than minutes. First,
the majority of recreational athletes for whom advice about caffeine ingestion is
provided by exercise scientists, probably compete in long-distance running and
cycling events, including marathons and triathlons, that last hours rather than min-
utes. Second, the effects of caffeine could conceivably differ depending not only on
the type of exercise undertaken (closed vs. open trials) but also on its duration.
Third, the method of action of caffeine could conceivably be different under differ-
ent circumstances. For example, it would be unlikely that a glycogen sparing effect
would explain any ergogenic effect of caffeine during exercise of short duration,
whereas that effect could be important during more prolonged exercise, lasting
some hours.
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Accordingly in this study, we evaluated the effects of caffeine ingestion on
performance during a 100-km cycling time trial, which included high intensity




Fifteen competitive, endurance-trained male cyclists volunteered for this study,
with 8 completing the full trial. Seven of the original 15 subjects were excluded—2
because they were unable to achieve the required cycling speed and 5 because they
found the trial “too arduous”. At the time of the study, the trialists were cycling
between 200–500 km · wk–1 and had completed at least one local, specified, annual
104-km road race under 3 hours during the previous 2 years. Subjects were well-
trained and accustomed to exercising for prolonged periods (3–4 hours). The mean
age, weight, body fat, V·O2max, and peak power output (PPO) of the 8 subjects who
completed the trial were 23.5 ± 6.7 years, 66.8 ± 6.2 kg, 10.6 ± 3.5%, 64.6 ± 7.9 ml ·
kg–1 · min–1 and 385 ± 61 W, respectively. All subjects were fully informed of the
nature of the investigation, which was to evaluate the effects of caffeine or carbohy-
drate drink ingestion on cycling performance, after which they gave written in-
formed consent. The study was approved by the Research and Ethics Committee of
the Faculty of Health Sciences within the University of Cape Town.
Kingcycle Ergometry System
All testing was conducted on a Kingcycle ergometry system (Kingcycle Ltd., High
Wycombe, UK), which allows cyclists to ride on their own racing bicycles in the lab-
oratory. After the front wheel was removed, the subject’s bicycle was attached to the
ergometry system by the front fork and supported by an adjustable pillar under the
bottom bracket. The bottom bracket support was used to position the rolling resis-
tance of the rear wheel correctly on an air-braked flywheel. A photo-optic sensor
monitored the velocity of the flywheel in revolutions per second (RPS), from which an
IBM-compatible computer calculated the power output (W) that would be gener-
ated by a cyclist riding at that speed on a level terrain, using the following equation:
W = 0.000136 RPS3 + 1.09 RPS
The Kingcycle was calibrated before both the incremental tests to exhaustion
and time trials. For the calibration, subjects were asked to accelerate to a workload
of ~200 W and instructed to immediately stop pedaling as soon as they reached the
desired workload, while remaining seated in their riding position. The bottom bracket
support was then adjusted until the computer display indicated that the slowing of
the flywheel matched a predetermined reference power decay curve. The time taken
for a laboratory simulated 20-km and 40-km time trials on the Kingcycle ergometer
system has previously been shown to be highly reproducible (CV 1.1 ± 0.9% and
1.0 ± 0.5%, respectively; 20, 32).
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Preliminary Testing
To determine PPO, the modified protocol as described by Hawley and Noakes (19)
was used. Subjects performed a 10-min warm up on the Kingcycle. The starting
power output was determined by multiplying the subject’s body weight by 3.3 W.
The load was subsequently increased at a rate of 1 W · kg–1 of body weight · 150 s–1.
The subject was required to match a continuously increasing power output dis-
played in analogue form on the computer monitor. The test was terminated when the
subject failed to match the target power. The highest mean power output achieved
during any 150-s period was recorded as the subject’s PPO. The PPO was subse-
quently converted into a predicted V·O2max value using the following equation as
described by Keen et al. (24):
V·O2max (L · min–1) = 0.011 PPO (W) + 0.081
Experimental Procedure
After measurement of the PPO, each subject reported to the laboratory on four
separate occasions. During the first visit, subjects familiarized themselves with the
equipment and laboratory conditions; thereafter, they completed a familiarization
100-km cycling time trial (TT), during which they ingested their own chosen fluid
replacement solutions (e.g., cordial, water, and sports drinks) ad libitum. All other
conditions were identical except that subjects were also not given tablets, nor were
they forced to drink at specific, regular intervals during the familiarization trial.
Subjects completed a TT during each of the next three visits. Each visit was sepa-
rated by a minimum of 6 and a maximum of 8 days.
For each subject, the 3 TTs were conducted at the same time of day in the
environmental chamber (Scientific Technology Corporation, Cape Town, South
Africa) at an ambient temperature of 27 °C, a relative humidity (Rh) of 50 ± 0.9%,
and a wind velocity (v) of 15 ± 0.4 km · h–1. The trials were randomized, and subjects
were blinded to the nature of each trial. The subjects were requested to perform the
same type of training for the duration of the trial and to refrain from heavy physical
exercise on the day before a TT. Subjects completed a nutritional information sheet
on which they recorded their food and fluid intake for 3 days preceding the TT.
Subjects were instructed to avoid any caffeine containing products for 48 hours
before each time trial. They were specifically asked to abstain from all the obvious
sources of caffeine including coffee, tea, cola drinks, chocolate, and over-the-counter
caffeine containing pharmaceuticals. They were requested to report any deviations
from these instructions. The day prior to the trial, the subjects followed a prescribed
diet, which consisted of 5 g · kg–1 of carbohydrate and 1.3 g · kg–1 protein (60% and
17%, respectively). They were instructed to repeat the same dietary regimen before
each subsequent trial.
In addition, before each experiment, subjects were issued a standardized
breakfast consisting of 30 g of cornflakes and 150 ml of 2% fat milk, which was
consumed 3 hours prior to commencing the TT. Only subjects who followed
the standardized dietary and training protocol were allowed to continue with
the study.
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Isometric Testing
To normalize EMG recordings during cycling, it was first necessary to perform
isometric testing. All subjects were tested on a Kin-Com isokinetic dynamometer
(Chattanooga Group Inc., U.S.). The knee extensors were tested isometrically at
stop and start angles of 60º and 65º, respectively. Each subject performed four
submaximal familiarization trials on the isokinetic dynamometer. Following the
warm-up, subjects performed three MVCs for each test. The highest average force
in these tests was used for subsequent analysis. The subjects were verbally encour-
aged during the test to exert maximal effort.
Electromyographic (EMG) Testing
Prior to maximal isometric strength testing on the Kin-Com isokinetic dynamom-
eter, EMG electrodes were attached to the subject’s lower limb midway between the
superior surface of the patella and the anterior superior iliac crest of the “belly” of
the rectus femoris as previously described (17). The electrodes were heavily taped
down and surrounded with cotton swabs to minimize sweat-induced interference.
The overlying skin on the muscles was carefully prepared. Hair was shaved off, the
outer layer of epidermal cells abraded, and oil and dirt were removed from the skin
with an alcohol swab. Triode electrodes were placed on the muscle sites as described
above and linked via a fiber-optic cable to the Flexcomp/DSP EMG apparatus
(Thought Technology, U.S.) and host computer. A 50-Hz line filter was applied to
the EMG data to prevent electrical interference from electrical sources. Each EMG
measurement was sampled at a 1984-Hz capture rate for both MVC and the cycle
TT. EMG was captured at 5-s bouts during MVC, whereas during the TT, four
successive bursts of EMG activity representing the cycle contractions were selected
to standardize measurement because subjects selected their own cadence. Four
bursts of consecutive raw EMG data from the cycle contractions were collected at
the midpoint of each 1-km HIE (10.5 km, 32.5 km, 52.5 km, 72.5 km, and 99.5 km)
and each 4-km HIE (22 km, 42 km, 62 km, and 82 km) during each TT. The raw
EMG data was automatically anti-aliased by the hardware (Thought Technology,
U.S.). Then the EMG signals were full-wave rectified, movement artifact removed
using a high-pass second-order Butterworth filter with a cutoff frequency of 15 Hz,
then smoothed with a low-pass second-order filter with a cutoff frequency of 5 Hz.
This was performed using MATLAB™ gait analyses software. This integrated data
(IEMG) was used for subsequent analyses.
Following isometric testing, the subjects ingested gelatin capsules containing
placebo (white flour) with 150 ml of either a sports electrolyte solution containing a
sweetener (1.7% carbohydrate; Pl) or the same solution with 7% carbohydrate
without sweetener (Cho), or gelatin capsules containing caffeine (6 mg · kg–1) with
the 7% carbohydrate solution (Caf). This caffeine dose was selected because it is
believed to produce an ergogenic effect without exceeding the International Olym-
pic Committee’s (IOC) legal limits (18). Moreover, caffeine doses of 5–6 mg · kg–1
bodyweight (BW) saturate the cytochrome P-450 system in the liver (17). Further-
more, because a considerable amount of caffeine is excreted through sweat during
endurance exercise (25) and as exercise increases the expression of cytochrome
P450 1A2 (45), decreasing peak plasma caffeine levels and half-life (7), it was
considered necessary that subjects also ingest a maintenance dose of 0.33 mg · kg–1
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BW of caffeine every 15 min during the Caf trial. This maintenance dose was
calculated to ensure that the overall caffeine dosage did not exceed 9 mg · kg–1 BW.
This dose maintains mean urinary caffeine levels below the IOC limit of 12 mg–1ml
(11, 16, 33, 43, 44). Hence a bolus amount of 6 mg · kg–1 BW caffeine allowed a
maintenance dose of 3 mg · kg–1 BW over the TT of approximately 2.5 hours. This
allowed 9 3 15-min dosages, each containing 0.33 mg · kg–1 BW. During the two
other trials (Pl and Cho), flour-containing gelatin tablets were ingested every 15
min. One hour after ingesting the initial solution and capsules, a resting blood
sample was taken and urine sample collected, and body weight was measured on a
precision scale (Soehnle, Germany).
After a standardized 5-min warm up of easy cycling, subjects commenced
with the 100-km time trial. Every 15 min the subjects were given either the caffeine
or placebo capsules together with 150 ml of either the carbohydrate or placebo
drinks. To mimic the stochastic nature of cycle road races, the time trial included a
series of HIE, during which subjects were requested to ride “as fast as possible”
according to the methods previously described (6). There were five 1-km HIE after
10, 32, 52, 72, and 99 km, as well as four 4-km HIE after 20, 40, 60, and 80 km.
Subjects were instructed to complete the total distance in “the fastest time possible”,
taking into consideration the HIE that were included. Just before commencement of
a sprint, the investigator gave a distance countdown and instructed the cyclist to
complete the HIE in the fastest possible time as soon as he reached the specific
distance at which the sprint started. Subjects viewed a diagram of the “course
profile”, which graphically illustrated where the 1-km and 4-km HIE occurred,
before and during each ride. Otherwise subjects received no external clues to influ-
ence their performance other than their elapsed distance and heart rate. Subjects
were not informed of the elapsed time or the times for the HIE until completion of all
three trials.
Throughout each trial, power output and elapsed time were monitored con-
tinuously and stored on computer. Heart rate was recorded using a Sport Tester
monitor (Polar Electro, Kempele, Finland). Instantaneous power output and heart
rate was recorded at each 500-m split of both the 1-km and 4-km HIE to provide an
estimate of the average power output for the HIE. Rating of perceived exertion
(RPE; 4) was recorded in the middle of each HIE.
Upon completion of the TT, subjects had their bodyweight recorded, urine
sample collected, and a final blood sample drawn. Finally, subjects were asked
whether they could determine which solution, caffeine or placebo, they had re-
ceived and to describe the basis on which they made that choice.
Analysis
Blood Samples
Fifteen milliliter venous blood samples were drawn by venepuncture into EDTA,
sodium fluoride and potassium oxalate, and SST® gel clot activator vacutainer tubes
for determinations of caffeine, lactate, and free fatty acid (FFA) concentrations,
respectively. Immediately after the completion of the trial, the tubes were centri-
fuged at 3000  g for 10 min at 4 ºC, and the supernatants were stored at –20 ºC for
later analyses. Plasma lactate concentrations were measured with spectrophotomeric
(Beckman Model 35, Beckman Instruments Inc., Fullerton, CA) enzymatic assay
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[Lactate PAP, BioM (Rieux, Lyon, France) NEFA half-micro test (Boehringer
Manheim, Germany)]. Serum FFA concentrations (FFA one and a half–micro test,
Boehringer Manheim, Germany) were also determined by spectrophotomeric enzy-
matic assay using commercial kits. Plasma caffeine, theophylline, paraxanthine,
and theobromine concentrations were measured using high-performance liquid chro-
matography (HPLC; Gilson Inc., Middleton, WI). Plasma samples were processed
as described by Tang-Liu et al. (42) with modifications. Briefly, plasma proteins
were precipitated by the gradual addition of 2 ml of acetonitrile to 0.5 ml of plasma
containing 20 ml of 1 mg–1 ml paracetomol as an internal standard. The samples
were mechanically agitated and centrifuged at 3000  g for 5 min, and the superna-
tants were transferred to a fresh tube, frozen in liquid nitrogen, and freeze dried for at
least 24 hours. The dried samples were resuspended in 200 l of the mobile phase
(90 mM phosphate, pH 3.6; 2.3 mM tetrabutyl ammonium hydrogen sulphate; 6%
acetonitrile) and stored at 4 ºC until HPLC analysis. Twenty l of each sample was
injected and resolved on a 150  4.6 mm Ultracarb 5 ODS (20) analytical column
protected by 30  4.6 mm ultracarb 5 ODS (20) guard column (Phenomenex, St.
Torrance, CA). The methylxanthine samples were measured at 280 nm.
EMG
The spectrum of the frequency for each epoch of data collected during the TT HIE
was assessed using the raw EMG data by using a fast Fourier transformation algo-
rithm. The analyses for frequency spectrum were restricted to frequencies of the 5–
500 Hz range, due to the EMG signal content consisting mostly of noise when it is
outside of this bandwidth. The frequency spectrum from each epoch of data was
compared with that derived from the MVC, and the amount of spectral compression
was estimated. This technique was performed as described by Lowery et al. (27),
which is a modification of the work of Lo Conte and Merletti (26) and Merletti and
Lo Conte (30). The spectrum of the raw signal of each epoch was obtained and the
normalized cumulative power at each frequency was calculated for each epoch. The
shift in percentile frequency was then examined (i.e., at 0%, . . . 50%, . . . 100% of the
total cumulative). The percentile shift was then estimated by calculating the mean
shift in all percentile frequencies throughout the mid-frequency range (i.e., 5–500
Hz). This method has been suggested as a more accurate estimate of spectral com-
pression than median frequency analyses, which uses single value of (50th) percen-
tile frequency (27). This change in mean percentile frequency (MPFS) data was
used for subsequent analyses.
All EMG data were normalized by dividing the value obtained midway during
each HIE in the TT by the EMG value obtained during the MVC performed before
the start of each TT. IEMG and MPFS data were therefore expressed as a percentage
of this MVC data.
Statistical Analyses
Data are presented as means and standard deviations. A two-way ANOVA for
repeated measures was used to evaluate statistical significance of all the variables
measured. A Scheffe’s post hoc test was used to reduce the possibility of incurring a
type I error and automated checks for spericity were computed by the Statistica
program. The data was analyzed by a 3 (condition)  5 (time) and 3 (condition)  4
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(time) ANOVA for the 1-km and the 4-km HIE, respectively. Significance was
accepted at p ≤ .05.
Results
Plasma and Urinary Caffeine Concentrations
Subjects had low plasma caffeine concentrations in both non-caffeine trials, con-
firming their abstinence from caffeine-containing products before the trial (Table
1). Plasma caffeine and its metabolite paraxanthine concentrations were signifi-
cantly higher during, and over time, in Caf compared to both Pl or Cho trials (p < .01;
Table 1). Plasma theophylline and theobromine concentrations were also higher (p
< .05) in Caf versus Cho and over time between Caf versus Cho (Table 1).
Performance
Due to technical difficulties with the Kingcycle instrumentation, average power
was not recorded during the familiarization ride. TT performance measured as
average power during the TT or as time to complete the TT was not different in the
three trials (Figure 1). The fastest average finishing time, although not significant,
occurred during the familiarization trial when subjects ingested their own fluid
solutions ad libitum. There was no significant differences in any of the HIE times
Table 1 Plasma Concentrations of Caffeine and Its Metabolites Before and
After the 100-km Cycle Time Trials for Both Carbohydrate and Caffeine,
When Subjects Ingested Either Placebos (Pl), Carbohydrate and Placebo
(Cho), or Carbohydrate and Caffeine (Caf) During Exercise
Pl Cho Caf
Variable Pre Post Pre Post Pre Post
Caffeine 4.6 ± 7.2 2.5 ± 4.9 0.4 ± 0.6 1.1 ± 1.8 47.3 ± 12** 73 ± 27.8**
(M)
Theophylline 0.7 ± 0.6 0.5 ± 0.5 0.3 ± 0.4 0.5 ± 0.6 1.9 ± 2.1† 4.2 ± 4.7†
(M)
Paraxanthine 1.4 ± 1.2 1.3 ± 1.4 0.7 ± 0.4 0.6 ± 0.8 3.9 ± 2.8** 9.3 ± 7.2**
(M)
Theobromine 1.6 ± 2.3 1.4 ± 2 0.6 ± 0.7 0.5 ± 0.5 1.6 ± 1.1* 2.7 ± 1.3*
(M)
Note. Values are means ± SD. *Significant differences (p < .05) were found in the interaction
of Caf versus Cho and changes over time; **highly significant differences (p < .01) Caf versus
Cho and Pl; †significant differences (p < .05) were found in the interaction of Caf versus Pl
and differences between groups.
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between Pl, Cho, and Caf for both 1 km and 4 km (Figure 2). The values ranged
from1.1 ± 1.2 min to 1.36 ± 1.3 min for 1-km HIE and from 5.22 ± 5.4 min to 6.05 ±
5.8 min for 4-km HIE.
Heart Rate
There was a trend for mean heart rates to be higher during the 1-km HIE in Caf
compared to Pl or Cho; this trend became significant during the 4-km HIE (p < .05).
Heart rate in all groups responded similarly over time. Mean heart rates during both
the 1-km (184.0 ± 9.8 Caf; 177.0 ± 5.8 Pl; 177.4 ± 8.9 Cho) and 4-km (181.7 ± 5.7
Caf; 174.3 ± 7.2 Pl; 175.6 ± 7.6 Cho) HIE were similar under the different trial
conditions and tended to fall with successive HIE. Mean heart rate for the 100 km
was significantly higher (p < .01) in the Caf group compared to the Cho group
(181.6 ± 1.9 Caf; 175.5 ± 2.7 Cho).
EMG
Due to technical difficulties with the EMG instrumentation, complete EMG data
could only be collected for Cho and Caf. IEMG is expressed as a percentage of the
Figure 1 — Average power (W; top) and total time (mins; bottom) to complete familiar-
ization (Famil; top only), placebo (Pl), carbohydrate (Cho), and caffeine 100-km cycle
time trials.
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IEMG recorded during the MVC. There were no significant differences in IEMG
values in any of the HIE for Caf or Pl. The values ranged between 15.2 ± 1.0% and
41.3 ± 17.3% in the 1-km HIE and between 19.9 ± 4.4% and 26.3 ± 7.7% in the 4-km
HIE. There were no differences between groups or over time. The mean IEMG was
25.4 ± 18.3% for 1-km and 22.0 ± 13.2 for 4-km HIE. The MPFS, expressed as a
percentage of the MPFS measured during the MVC, also showed no differences
between group or time. The mean MPFS was 1.08 ± 0.2% for 1 km and 1.10 ± 0.2%
for 4 km.
Serum FFA and Lactate Concentrations
Serum FFA and lactate concentrations increased significantly during exercise in all
TT (p < .01). There were no differences in serum FFA and lactate concentrations
between groups. Mean pre FFA and lactate values for all three groups were 0.22 ±
0.1 mmol · L–1 and 1.33 ± 0.2 mmol · L–1, respectively, compared to post values of
1.7 ± 0.2 mmol · L–1 for FFA and 4.5 ± 0.4 mmol · L–1 for lactate.
RPE
RPE values rose progressively (p < .01) in successive 1-km and 4-km HIE. Mean
RPEs were also similar in the consecutive 1-km (19.8 ± 0.4 Caf; 19.6 ± 0.5 Pl; 18.7 ±
1.5 Cho) and 4-km (18.4 ± 1.9 Caf; 18.2 ± 1.8 Pl; 18.5 ± 1.5 Cho) HIE, but there was
no difference between Pl, Cho, and Caf.
Weight Loss
The percent weight loss of subjects during the three trials (3.5 ± 1.8% Caf; 3.0 ±
1.7% Pl; 2.7 ± 1.5% Cho) were similar.
Drug Identification
Seven of the 8 subjects correctly identified when they had ingested caffeine—citing
symptoms of reduced concentration and elevated heart rate—before, during, and
after the trial and difficulty in sleeping the following night.
Discussion
Caffeine is listed as a stimulatory drug by the International Olympic Committee
(IOC), and its use during those sporting competitions sanctioned by the IOC is
subject to certain restrictions. It is inherent in this assumption that any stimulatory
effect of caffeine will be performance enhancing.
Indeed the bulk of current evidence suggests that caffeine ingestion enhances
performance to quite a marked extent during more prolonged endurance exercise
(40), although there appears to be little if any effect during high intensity exercise of
short duration (10, 14, 18, 34), a fact which seems to have escaped the attention of
the international doping control authorities.
However, most of the evidence for this large effect comes from studies in
which subjects begin exercise unaware of any fixed endpoint other than to continue
exercising for “as long as possible” (16). One result is that subjects do not have a
fixed goal around which to plan their pacing strategy. We (38) and others (29) have
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shown that the coefficient of variance for such open-end testing is large. In contrast,
performance during closed trials, in which subjects begin exercise knowing the
endpoint in terms of distance to be covered or total exercise time, is far more
reproducible (37). In addition, relatively few studies have evaluated the effects of
caffeine on the performance of better performing athletes of the quality studied in
this trial and who, even then, were clearly not elite athletes of Olympic quality.
Accordingly, the most important finding of this study was that, in contrast to
the large ergogenic effect measured in open-ended trials, caffeine did not signifi-
cantly enhance overall performance during the 100-km cycling time trial that in-
cluded bouts of high intensity exercise. This is consistent with other trials which show
that any effect of caffeine is much greater in open-ended than closed trials. For example,
the magnitude of the ergogenic effect of caffeine in open-ended trials is of the order of
20–50% (17), whereas the average performance enhancement in closed trials was
1.8% (range, 1.7–2.5%; 3, 5, 25, 28, 46). In this study, subjects were 1.3% faster
when using caffeine compared to placebo, but 0.1% slower when ingesting caffeine
than in the familiarization trial when they ingested their chosen drinks ad libitum.
Plasma caffeine concentrations were low in the Pl and Cho trials but were
markedly elevated in the Caf trial; hence, illicit use of caffeine before the Pl or Cho
trials could not explain our failure to detect an ergogenic effect of caffeine. The
significantly higher heart rates with caffeine ingestion, especially during the 4-km
HIE, confirm that the ingested caffeine was physiologically active. In contrast, HIE
Figure 2 — Time taken to complete 1-km (top) and 4-km high intensity epochs (HIE)
(bottom) within the100-km cycle time trials for subjects ingesting placebo (Pl), carbo-
hydrate (Cho), or caffeine (Caf).
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performances when ingesting placebo or carbohydrate were reproduced exactly
(Figure 2).
Thus, despite only receiving heart rate as a external cue, subjects employed
essentially the same pacing strategies when ingesting either carbohydrate or pla-
cebo, whereas caffeine ingestion may have modified imperceptibly the pacing strat-
egy. Interestingly, in the studies of Bruce et al. (5), caffeine enhanced the perfor-
mance of rowers during a simulated 2000-m trial specifically by increasing their
speed only over the first 500 m of the race. This suggests that, in that trial, caffeine
may have acted directly on the subconscious brain centers that direct the early
pacing strategies during exercise.
Indeed, the noteworthy feature of this and other studies (33, 36, 37, 39) is the
reproducibility of the pacing strategies used by subjects during closed trials of the
type used in this study. This invites the question of the nature of the internal physi-
ological cues that determine such a response, since the subjects in all our trials
receive no external cues other than the distance covered.
In this study, we found that, whereas performance time (Figure 1) remained
unchanged, RPE rose progressively with consecutive 1-km and 4-km HIE, peak
heart rate was essentially the same, in both 1-km and 4-km HIE and, if anything,
decreased during the course of the exercise. Peak EMG activity was more variable,
in contrast to our previous study in which EMG activity was significantly lower in
the final 1-km and the last two 4-km HIE in subjects who modified their diets in the
3 days before exercise (9). However, sprinting performance in that trial also fell
significantly in the final 1-km and 4-km HIE, whereas in this study, performance
was unchanged in the successive 1-km and 4-km HIE (Figure 2).
Significantly, IEMG activity was about 12% higher during the 1-km than
during the 4-km HIE, which is to be expected since subjects cycled faster during the
1-km than the 4-km HIE. However, as also reported in our previous study (41),
subjects recruited only ~25% of their maximal neuromuscular activation during the
1-km sprints and only ~22% during the 4-km HIE.
Skeletal muscle activation and performance was greater in the 1-km than the
4-km HIE. However, if peripheral metabolite accumulation or muscle glycogen
depletion determines performance during the 4-km HIE or indeed the pacing strat-
egy during the sustained exercise between the HIE, then even higher performance
should not have been possible during the 1-km HIE. Rather, the higher metabolic
rate during the 1-km HIE should have increased the concentration of fatigue-induc-
ing metabolites, thereby progressively impairing performance. But this was not the
case (Figure 2).
Indeed in a previous study employing shorter 40-km time trials, which also
included repeated HIE, we (39) found that sprinting performance fell progressively
as did blood lactate concentrations, whereas pH rose, the opposite of the predicted
effect if fatigue is regulated by peripheral metabolites.
Furthermore, only 22–25% of the total neuromuscular activation was re-
cruited, even from the outset of the 1- and 4-km HIE. Hence, something “constrains”
neuromuscular activation so that less than 25% of the available muscle mass is ever
recruited, even from the start of exercise when muscle metabolite concentrations are
likely to be the least perturbed. We have proposed that this constraint exists centrally
in the brain (4, 23).
According to this theory, the consistency of performance in all these trials
results from a centrally-determined pacing strategy that is uninfluenced by caffeine
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ingestion. Since the neuromuscular activation does not rise during the repetitive
sprints, the absence of a “peripheral” fatigue is confirmed, since the definition of
peripheral fatigue requires a greater neuromuscular activation to maintain the same,
or a lesser, power output (31).
In summary, this study establishes that a substance considered ergogenic
because of its stimulatory effects on the central nervous system and shown to have
this effect during prolonged open-ended exercise (8, 12, 16, 17, 21, 33), fails to
improve performance when the trial has a defined endpoint.
If this is true, the IOC ruling on stimulatory drugs needs to be reviewed.
Indeed, we have previously shown that another substance banned by the IOC,
pseudoephedrine, did not improve 40-km time-trial performance (13). Now we
show the same result, but at a longer distance, for caffeine.
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